Cardiff Oncology reports FY2022 cash of $105.3M; provides clinical updates for onvansertib

Cardiff Oncology, Inc.

Cash, cash equivalents, and short-term investments $105.3M at Dec 31, 2022; projected runway into 2025.
Total operating expenses $40.3M for FY2022, up $11.1M from FY2021; net cash used in operations $33.8M.
Phase 1b/2 mCRC trial: ORR 35% (n=48), median PFS 9.3 months; bevacizumab-naïve subgroup ORR 69%, mPFS 13.5 months.
Appointed Fairooz Kabbinavar as CMO, Tod Smeal as CSO, Charles Monahan as SVP Regulatory Affairs.
Upcoming data readouts: mPDAC and SCLC in Q2/Q3 2023; TNBC in Q4 2023/Q1 2024; ONSEMBLE mCRC randomized data in Q3/Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cardiff Oncology, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-006049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.